OBJECTIVE: To compare the cost of illness of three musculoskeletal conditions in relation to general wellbeing. METHODS:Patients with fibromyalgia, chronic low back pain (CLBP), and ankylosing spondylitis who were referred to a specialist and participated in three randomised trials completed a cost diary for the duration of the study, comprising direct medical and non-medical resource utilisation and inability to perform paid and unpaid work. Patients rated perceived wellbeing (0-100) at baseline. Univariate differences in costs between the groups were estimated by bootstrapping. Regression analyses assessed which variables, in addition to the condition, contributed to costs and wellbeing. RESULTS:70 patients with fibromyalgia, 110 with chronic low back pain, and 111 with ankylosing spondylitis provided data for the cost analyses. Average annual disease related total societal costs per patient were 7813 euro for fibromyalgia, 8533 euro for CLBP, and 3205 euro for ankylosing spondylitis. Total costs were higher for fibromyalgia and CLBP than for ankylosing spondylitis, mainly because of cost of formal and informal care, aids and adaptations, and work days lost. Wellbeing was lower in fibromyalgia (mean, 48) and low back pain (mean, 42) than in ankylosing spondylitis (mean, 67). No variables other than diagnostic group contributed to differences in costs or wellbeing. CONCLUSIONS: In patients under the care of a specialist, there were marked differences in costs and wellbeing between those with fibromyalgia or CLBP and those with ankylosing spondylitis. In particular, direct non-medical costs and productivity costs were higher in fibromyalgia and CLBP.
RCT Entities:
OBJECTIVE: To compare the cost of illness of three musculoskeletal conditions in relation to general wellbeing. METHODS:Patients with fibromyalgia, chronic low back pain (CLBP), and ankylosing spondylitis who were referred to a specialist and participated in three randomised trials completed a cost diary for the duration of the study, comprising direct medical and non-medical resource utilisation and inability to perform paid and unpaid work. Patients rated perceived wellbeing (0-100) at baseline. Univariate differences in costs between the groups were estimated by bootstrapping. Regression analyses assessed which variables, in addition to the condition, contributed to costs and wellbeing. RESULTS: 70 patients with fibromyalgia, 110 with chronic low back pain, and 111 with ankylosing spondylitis provided data for the cost analyses. Average annual disease related total societal costs per patient were 7813 euro for fibromyalgia, 8533 euro for CLBP, and 3205 euro for ankylosing spondylitis. Total costs were higher for fibromyalgia and CLBP than for ankylosing spondylitis, mainly because of cost of formal and informal care, aids and adaptations, and work days lost. Wellbeing was lower in fibromyalgia (mean, 48) and low back pain (mean, 42) than in ankylosing spondylitis (mean, 67). No variables other than diagnostic group contributed to differences in costs or wellbeing. CONCLUSIONS: In patients under the care of a specialist, there were marked differences in costs and wellbeing between those with fibromyalgia or CLBP and those with ankylosing spondylitis. In particular, direct non-medical costs and productivity costs were higher in fibromyalgia and CLBP.
Authors: A Spoorenberg; D van der Heijde; E de Klerk; M Dougados; K de Vlam; H Mielants; H van der Tempel; S van der Linden Journal: J Rheumatol Date: 1999-04 Impact factor: 4.666
Authors: Astrid Van Tubergen; Annelies Boonen; Robert Landewé; Maureen Rutten-Van Mölken; Désirée Van Der Heijde; Alita Hidding; Sjef Van Der Linden Journal: Arthritis Rheum Date: 2002-10-15
Authors: A Boonen; D van der Heijde; R Landewé; A Spoorenberg; H Schouten; M Rutten-van Mölken; F Guillemin; M Dougados; H Mielants; K de Vlam; H van der Tempel; Sj van der Linden Journal: Ann Rheum Dis Date: 2002-05 Impact factor: 19.103
Authors: A Boonen; D van der Heijde; R Landewé; F Guillemin; M Rutten-van Mölken; M Dougados; H Mielants; K de Vlam; H van der Tempel; S Boesen; A Spoorenberg; H Schouten; Sj van der Linden Journal: Ann Rheum Dis Date: 2003-08 Impact factor: 19.103
Authors: Rebecca L Robinson; Howard G Birnbaum; Melissa A Morley; Tamar Sisitsky; Paul E Greenberg; Ami J Claxton Journal: J Rheumatol Date: 2003-06 Impact factor: 4.666
Authors: M Kivimäki; P Leino-Arjas; L Kaila-Kangas; M Virtanen; M Elovainio; S Puttonen; L Keltikangas-Järvinen; J Pentti; J Vahtera Journal: Ann Rheum Dis Date: 2006-06-22 Impact factor: 19.103
Authors: S M M Verstappen; J W G Jacobs; D M van der Heijde; Sj van der Linden; C M Verhoef; J W J Bijlsma; A Boonen Journal: Ann Rheum Dis Date: 2006-12-15 Impact factor: 19.103
Authors: W Eich; W Häuser; E Friedel; A Klement; M Herrmann; F Petzke; M Offenbächer; M Schiltenwolf; C Sommer; T Tölle; P Henningsen Journal: Schmerz Date: 2008-06 Impact factor: 1.107
Authors: Ana Assumpção; Alane B Cavalcante; Cristina E Capela; Juliana F Sauer; Suellen D Chalot; Carlos A B Pereira; Amélia P Marques Journal: BMC Musculoskelet Disord Date: 2009-06-08 Impact factor: 2.362